Combination therapy strategies have shown significant advantages in the treatment of osteosarcoma, and combining therapy targeting the NF-κB pathway with chemotherapy can play a synergistic role to improve the therapeutic effect (190). This evidence concerns the gene NFKB1 and osteosarcoma.